Genmab A/S (GMAB): Price and Financial Metrics

Genmab A/S (GMAB): $42.05

-0.98 (-2.28%)

POWR Rating

Component Grades













Add GMAB to Watchlist
Sign Up

Industry: Biotech


of 505

in industry


  • Quality is the dimension where GMAB ranks best; there it ranks ahead of 79.16% of US stocks.
  • The strongest trend for GMAB is in Momentum, which has been heading down over the past 48 weeks.
  • GMAB's current lowest rank is in the Momentum metric (where it is better than 9.5% of US stocks).

GMAB Stock Summary

  • Of note is the ratio of Genmab A's sales and general administrative expense to its total operating expenses; merely 8.58% of US stocks have a lower such ratio.
  • With a price/sales ratio of 25.26, Genmab A has a higher such ratio than 91.74% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.12 for Genmab A; that's greater than it is for just 8.7% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Genmab A, a group of peers worth examining would be ERYP, LEGN, CANF, OMEX, and HIMX.
  • Visit GMAB's SEC page to see the company's official filings. To visit the company's web site, go to

GMAB Stock Price Chart Interactive Chart >

Price chart for GMAB

GMAB Price/Volume Stats

Current price $42.05 52-week high $49.07
Prev. close $43.03 52-week low $30.10
Day low $41.95 Volume 193,800
Day high $42.39 Avg. volume 514,583
50-day MA $45.46 Dividend yield N/A
200-day MA $40.34 Market Cap 27.62B

Genmab A/S (GMAB) Company Bio

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its portfolio includes two products, daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

GMAB Latest News Stream

Event/Time News Detail
Loading, please wait...

GMAB Latest Social Stream

Loading social stream, please wait...

View Full GMAB Social Stream

Latest GMAB News From Around the Web

Below are the latest news stories about Genmab A that investors may wish to consider to help them evaluate GMAB as an investment opportunity.

Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co. Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co.

Intrado Digital Media | September 24, 2021

Nasdaq Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise

The share capital of Genmab A/S has been increased. The admittance to trading and official listing will take effect as per 24 September 2021 in the ISIN below. ISIN: DK0010272202 ------------------

FinanzNachrichten | September 23, 2021

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 21, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 3,969 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 1,800 shares at DKK 337.40,1,875 shares at DKK 939.50,144 shares at DKK 1,145.00, and150 shares at DKK 1,210.0

Yahoo | September 21, 2021

FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer

The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S’ (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The nod comes for second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-(L)1 systemic therapy. Read Next: Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer. Tivdak is an antibody-drug conjugate (ADC) that links a tissue factor-directed antibody with a payload of monom

Yahoo | September 21, 2021

Genmab, Seagen, Lennar, SmileDirect See After-Hours Moves

Drug makers gain on accelerated FDA approval for a cervical cancer treatment.

The Street | September 20, 2021

Read More 'GMAB' Stories Here

GMAB Price Returns

1-mo -10.70%
3-mo 2.99%
6-mo 27.66%
1-year 13.80%
3-year 166.98%
5-year 150.33%
YTD 3.42%
2020 82.09%
2019 35.54%
2018 -0.61%
2017 -0.04%
2016 23.73%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.876 seconds.